RHEPOTCLessors of Real Property, NECFiscal year ends December 31Also trades as RHEPA, RHEPB, RHEPZ
REGIONAL HEALTH PROPERTIES, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.04+0.00 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $4.09M
- P/E (TTM)
- 1.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
3.1%−9.9 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +189.9% | +14.0% | +24.8% | +11.2% | |
| Operating income | +933.5% | – | -6.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 24.2% | -6.0% | – | |
| Return on assets | -5.2% | -0.6% | – | |
| Current ratio | 0.81 | – | 0.67 | |
| Debt to equity | -2.11 | 4.90 | 115.05 | |
| Net debt to EBITDA | 6.16× | 9.05× | 9.96× | |
| Interest coverage | 0.6× | 0.8× | 0.6× | |
| Capex to revenue | 5.4% | 2.6% | 1.6% | |
| Diluted shares | 2M | 2M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Regional Health Properties generated $16.41M from operations and spent $2.81M on capital expenditure, dividends and share buybacks. 98% of that went back into the business.
Generated
$16.41M
Used
$2.81M
Capital expenditure$2.76M98%Dividends$00%Share buybacks$53.00K2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-22.7%
×Asset turnover0.26×
×Equity multiplier33.52×
=Return on equity, FY2023-199.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -22.7% | 0.26× | 33.52× | -199.3% |
| FY2022 | -19.1% | 0.41× | 12.35× | -97.3% |
| FY2021 | -4.4% | 0.25× | 9.94× | -11.0% |
| FY2020 | -3.9% | 0.16× | 9.71× | -6.0% |
| FY2019 | 27.3% | 0.19× | 11.98× | 61.5% |
| FY2018 | -54.0% | 0.21× | 8.62× | -99.0% |
| FY2017 | -3.9% | 0.22× | -11.26× | 9.8% |
| FY2016 | -27.0% | 0.19× | -4.67× | 24.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$2.26M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$2.26M vs –
- Less leverageLong-term debt to assets fell65.0% → 51.2%
- Better liquidityCurrent ratio rose0.33 → 0.67
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → 86.87%
- More efficientAsset turnover rose0.29 → 0.88